Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium

Abstract

Background: Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist for the treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind study compared the bronchodilator efficacy of indacaterol with that of placebo and tiotropium in patients with moderate-to-severe COPD.

Methods: In an incomplete-block, multi-dose, three-period, crossover design, patients received three of the following four treatments: indacaterol 150 μg, indacaterol 300 μg, tiotropium 18 μg and placebo, each once-daily for 14 days. Each treatment period was separated by a 14-day washout. Study drug was supplied daily by blinded, third party study personnel to maintain blinding of patients and investigators. The primary efficacy variable was trough forced expiratory volume in one second (FEV1) at 24 h post-dose after 14 days. The study was powered to demonstrate non-inferiority of indacaterol to tiotropium for this variable.

Results: A total of 169 patients were randomized (mean age 65 years); 153 (90.5%) completed. Trough FEV1 after 14 days with indacaterol 150 μg and 300 μg was statistically and clinically superior to placebo, with differences (95% CI) of 170 (120-220) and 150 (100-200) mL respectively (both p < 0.001). For this endpoint, both doses of indacaterol not only met the criterion for non-inferiority compared with tiotropium, but also achieved numerically higher values, with differences versus tiotropium of 40 and 30 mL for indacaterol 150 and 300 μg, respectively. At 5 min post-dose on Day 1, the mean FEV1 for both indacaterol doses was significantly higher than placebo (by 120 and 130 mL for indacaterol 150 and 300 μg, respectively; p < 0.001) and tiotropium (by 80 mL for both doses; p < 0.001). Adverse events were reported by similar proportions of patients: 31.4%, 29.5%, 28.3% and 28.5% for indacaterol 150 μg and 300 μg, tiotropium and placebo treatments, respectively.

Conclusions: Once-daily indacaterol provided clinically and statistically significant 24-h bronchodilation. Indacaterol was at least as effective as tiotropium, with a faster onset of action (within 5 min) on the first day of dosing. Indacaterol should prove useful in patients with moderate-to-severe COPD, for whom treatment with one or more classes of long-acting bronchodilator is recommended.

Trial registration: ClinicalTrials.gov: NCT00615459, EudraCT number: 2007-004071-19.

Figure 1

24-h post-dose (trough) FEV₁ (L) after 14 days of treatment (mITT population). Data are LSM ± SE. ***p < 0.001 vs placebo; ^†p = 0.043 vs tiotropium. FEV₁, forced expiratory volume in 1 s

Figure 2

24-h profile of least squares means of FEV₁ on Day 1 (A) and 14 (B) (mITT population). A) Data are LSM ± SE. p < 0.001 for indacaterol (150 and 300 μg) vs placebo at each timepoint, p < 0.001 for indacaterol, 150 μg vs tiotropium at 5 and 15 min, ^†p < 0.05 for indacaterol 300 μg vs tiotropium, p < 0.05 for tiotropium vs placebo at each timepoint. B) Data are LSM ± SE. p < 0.001 for indacaterol (150 and 300 μg) and tiotropium vs placebo at each timepoint, ^†p < 0.05 for indacaterol 150 μg vs tiotropium at -50 to 30 min, 12 h and 23 h 10 min, p < 0.05 for indacaterol 300 μg vs tiotropium at 5 min